TME Pharma Adopts All Resolutions at 2026 Annual General Meeting Amid Strategic Out-Licensing Push
Key Insights
TME Pharma (search) shareholders unanimously adopted all resolutions at the Annual General Meeting held on June 15, 2026, with 6.87% of voting rights represented.
The clinical-stage biotech is actively seeking out-licensing opportunities and alternative funding to advance its lead assets NOX-A12 and NOX-E36.
NOX-A12, an anti-CXCL12 (search) L-RNA aptamer, holds FDA Fast Track Designation for glioblastoma (search) and has completed a Phase 1/2 GLORIA study currently on hold.
TME Pharma (search) N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on novel therapies for brain cancer and eye diseases, announced on June 17, 2026 that all resolutions were unanimously adopted at its Annual General Meeting (AGM) held on June 15 in Berlin, Germany. The meeting, chaired by Mr. Diede van den Ouden, saw four shareholders present, granting proxies or voting by mail, collectively representing 6.87% of the company's shares and voting rights.
The unanimous adoption of all resolutions submitted by the Board of Directors signals shareholder alignment as the company navigates a critical period of strategic repositioning. TME Pharma (search) is currently seeking opportunities to secure financial resources to unlock the value of its two lead assets, NOX-A12 and NOX-E36.
Lead Asset NOX-A12: Targeting Glioblastoma (search)
NOX-A12 (olaptesed pegol), an anti-CXCL12 (search) L-RNA aptamer, represents TME Pharma (search)'s most clinically advanced program. The compound is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair.
NOX-A12 has been studied in the GLORIA Phase 1/2 clinical trial (NCT04121455), a dose-escalation study evaluating the drug in combination with radiotherapy in first-line partially resected or unresected glioblastoma (search) patients with unmethylated MGMT promoter — a population resistant to standard chemotherapy. The study, currently on hold, also includes an expansion arm evaluating NOX-A12 combined with radiotherapy and bevacizumab.
The U.S. FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma (search). Additionally, the FDA awarded Fast Track Designation to NOX-A12 in combination with radiotherapy and bevacizumab for the treatment of aggressive adult glioblastoma. The drug, in combination with radiotherapy, had also previously received orphan drug designation for glioblastoma in the United States and glioma in Europe.
NOX-E36: Ophthalmic and Anti-Fibrotic Potential
TME Pharma (search)'s second lead compound, NOX-E36 (emapticap pegol), is an L-RNA aptamer that inhibits CCL2 (search) and related chemokines. The company is evaluating this asset in ophthalmic diseases characterized by a high need for well-tolerated therapies with anti-fibrotic effect.
Planned Expansion into Pancreatic Cancer (search)
Beyond glioblastoma (search), TME Pharma (search) has designed the OPTIMUS study (NCT04901741), a planned open-label two-arm Phase 2 trial of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in patients with microsatellite-stable metastatic pancreatic cancer (search).
Strategic Financial Path Forward
With the GLORIA study on hold, TME Pharma (search) is pursuing multiple avenues to secure its financial future, including raising funds from alternative sources, pursuing stable cash-generating business opportunities to achieve positive operational cash flow, and leveraging tax loss carry forwards. The company is actively seeking to out-license both NOX-A12 and NOX-E36 to partners capable of advancing these programs through later-stage development.